Last reviewed · How we verify
NCT07441005
Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment of Tinea CrurisAbstract
EARLY_PHASE1 trial testing Topical Oxiconazole cream in Tinea Cruris in 386 participants. Completed in 15 October 2025.
15 October 2025
Quick facts
| Lead sponsor | Hayat Abad Medical Complex, Peshawar |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 386 |
| Start date | 15 May 2025 |
| Primary completion | 15 October 2025 |
| Estimated completion | 15 October 2025 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Topical Oxiconazole cream — full drug profile →
- Topical Clotrimazole cream — full drug profile →
Conditions studied
- Tinea Cruris — all drugs for Tinea Cruris →
Sponsor
Hayat Abad Medical Complex, Peshawar — full company profile →
Who can join
Adults 18 to 70, any sex, with Tinea Cruris. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is conducted to compare the efficacy of topical oxiconazole 1% cream versus topical clotrimazole 1% cream in patients with tinea cruris.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07441005
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tinea Cruris
Currently open trials in the same condition.
- NCT07312604 — A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Rec · NA · recruiting
Other Hayat Abad Medical Complex, Peshawar trials
Trials by the same sponsor.
- NCT07055529 — Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of General · EARLY_PHASE1 · not yet recruiting
- NCT07453238 — Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata · Phase 4 · not yet recruiting
- NCT07437534 — Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) fo · Phase 4 · not yet recruiting
- NCT07406204 — Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA) · Phase 4 · not yet recruiting
- NCT06847841 — Cost-Effectiveness and Clinical Outcomes of Double J Stent Versus Percutaneous Feeding Tube Placement Following Open Pye · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07441005 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hayat Abad Medical Complex, Peshawar
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07441005.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing